Navigation Links
Yongye International Announces First Quarter 2010 Results
Date:5/12/2010

-term debt. Stockholders' equity totaled $145.8 million as of March 31, 2010, compared to $132.6 million at the end of 2009.

    Recent Developments
    -- In May 2010, Yongye announced that the Company started the construction
       of a new production facility in Wuchuan County, Hohhot Municipal City,
       Inner Mongolia Autonomous Region.
    -- In March 2010, Yongye announced that both the Company's plant and
       animal nutrient products won the "Special Houji Award" at the 16th
       annual China Yangling Agricultural Hi-Tech Fair (the "CAF") in December
       2009.
    -- In March 2010, Yongye signed an agreement to acquire the development
       rights for a lignite coal resource project in Inner Mongolia, PRC for
       $35.1 million.

Business Outlook

From 2010 to 2012, Yongye expects to achieve at least a 50% annual growth rate in revenue. The Company also reaffirms its previously issued guidance. The Company expects 2010 annual revenues of between $160 million and $165 million, representing an increase of between 63% and 68% over last year's revenue of $98.1 million. The Company expects adjusted net income, which excludes the impact of certain non-cash expenses such as the change in fair value of warrants and share-based compensation, of between $42 million and $45 million, representing an increase of between 60% and 72% over 2009 adjusted net income of $26.2 million. The Company also reaffirms its previously announced estimate that the number of independently-owned, branded stores selling Yongye's Shengmingsu products will increase to at least 20,000 by the end of 2010, which represents a 120% increase over the 2009 year-end figure of 9,110.


'/>"/>
SOURCE Yongye International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Yongye International Announces Conference Call to Discuss First Quarter Fiscal Year 2010 Results
2. Yongye International to Present at Upcoming Investor Conferences
3. Yongye International, Inc. Begins Construction of New Production Facility
4. Yongye International Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Results
5. Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
6. Yongye International Announces 2010-2012 Strategic Plan
7. Yongye International Announces Expansion of Research and Development Center
8. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
9. Yongye Biotechnology International Receives License to Manufacture Products
10. Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
11. Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... 2015 GEA Pharma Systems, G-CON ... recipients of the INTERPHEX Exhibitor Awards for 2015 ... Portable, Continuous, Miniature and Modular (PCMM) platform. PCMM ... continuous processing equipment, smart control systems and PODs ... and inactive ingredients into bulk tablets. , ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Synedgen ... Nguyen, PhD as Regulatory Affairs Manager. , Dr. Nguyen ... an important juncture for the company as it moves ... drug products over the next two years. Dr. Nguyen ... of all the regulatory key documents that must be ...
(Date:5/4/2015)... , May 4, 2015 Many of ... But for certain infants with rare, inherited mutations ... stark consequences of their impaired immune responses. ... have identified an important role for calcium signaling ... Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Synedgen Announces the Appointment of Regulatory Affairs Manager 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
... Limited (NasdaqCM: PRAN) (ASX: PBT.AX), a biopharmaceutical,company ... treatments for,neurodegenerative disorders, today announced it has ... statements for the year ended,June 30, 2007, ... The annual,report its available on Prana,s website ...
... VaxGen,Inc. (Pink Sheets: VXGN) announced today that ... Directors as a result of accepting the CEO,position ... that Mr.,Anthony relinquish all corporate directorships in accepting ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) "On behalf of ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4Jack Anthony to Resign From VaxGen's Board After Accepting CEO Position at Osprey Pharmaceuticals 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... tissue-engineered trachea (windpipe), utilising the patient,s own stem ... woman with a failing airway. The bioengineered trachea ... airway, thereby saving her life. These ... stem cells, combined with biologically compatible materials, can ...
... breakthrough against cancer, infectious diseases, or metabolic conditions like ... drugs, and even if they do clinical development usually ... medical research is conducted in highly fragmented groups focusing ... turn out not to work properly or to have ...
... created by a University of Central Florida professor show ... Professor James Turkson,s compounds disrupt the formation and spread ... The compounds, S3I-201 and S3I-M2001, break up a cancer-causing ... side effects so far. "The compounds are very ...
Cached Biology News:Adult stem cell breakthrough 2Adult stem cell breakthrough 3Systems biology brings hope of speeding up drug development 2Systems biology brings hope of speeding up drug development 3Two new compounds show promise for eliminating breast cancer tumors 2
... tumor cells of embryonal carcinoma of testis and ... tumors like seminoma. Glandular epithelium of yolk sac ... endocrine cells of stomach and acini cells of ... Epitope: Carbohydrate portion on human embryonal ...
TP-1 (NDOG1)...
Ras-related C3 botulinum toxin substrate 1...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
Biology Products: